ralimetinib Report issue

Small molecule Experimental
AACT ChEMBL DrugBank PubChem

Active Ingredient History

NOW
  • Now
Ralimetinib (LY2228820) is a small molecule experimental cancer drug in development by Eli Lilly. Although originally thought to be a p38 mitogen-activated protein kinase (MAPK) inhibitor, it has since been reported that it acts instead as an epidermal growth factor receptor (EGFR) inhibitor.   Wikipedia

Chemistry

  • SMILES: CC(C)(C)Cn1c(N)nc2ccc(-c3[nH]c(C(C)(C)C)nc3-c3ccc(F)cc3)nc21
  • InChIKey: XPPBBJCBDOEXDN-UHFFFAOYSA-N
  • Mol. Mass: 420.54
  • ALogP: 5.55
  • ChEMBL Molecule:
    ralimetinib  
More Chemistry

Pharmacology

Alternative names

ly2228820 | ly-2228820 | ly-22288220 | ralimetinib

Organizations (5)

Research & Development (5)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (9)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (9)


 

Breast Neoplasms (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Carcinoma, Ovarian Epithelial (Phase 1/Phase 2)

Colorectal Neoplasms (Phase 1)

Fallopian Tube Neoplasms (Phase 1/Phase 2)

Glioblastoma (Phase 1/Phase 2)

Hamartoma (Phase 1/Phase 2)

Neoplasms (Phase 1)

Postmenopause (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial Organizations: 5

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue